Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06614270
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-24
Brief Title:
Anti-CD19 CAR-NK Cells in RefractoryRelapsed Autoimmune Diseases
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Anti-CD19 CAR-NK Cells in RefractoryRelapsed Autoimmune Diseases
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a single-center open-label single-arm dose-escalation trial The aim of this study is to investigate the safety and efficacy of anti-CD19 CAR-NK cells in patients with refractoryrelapsed autoimmune diseases including systemic sclerosis idiopathic inflammatory myositis ANCA associated vasculitis sjogren syndrome and antiphospholipid syndrome
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None